[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-332629-105":59,"doc-detail-332629-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","systemic-treatments-in-recurrent-or-metastatic-salivary-gland-cancer-a-systematic-review","Systemic treatments in recurrent or metastatic salivary gland cancer - a systematic review","","Salivary gland cancers are rare and biologically diverse, complicating the selection of optimal systemic therapy in advanced or relapsed settings. This systematic review evaluated overall survival and treatment response across four histologic types of salivary gland cancer, using a PubMed and Google Scholar search with PRISMA-based inclusion. From 723 screened studies, 44 were included, covering 426 recurrent or metastatic cases. Histomolecular markers linked strongly to histology, while receptor-targeted approaches showed subtype-specific effectiveness and treatment response correlated with improved survival.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/systemic-treatments-in-recurrent-or-metastatic-salivary-gland-cancer-a-systematic-review/332629/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/systemic-treatments-in-recurrent-or-metastatic-salivary-gland-cancer-a-systematic-review/332629.png","ImageObject",300,407,{"name":92,"@type":93},"River Wang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",15,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"What was the main goal of this systematic review?","Question",{"text":113,"@type":114},"To assess overall survival outcomes and systemic treatment responses across four types of salivary gland cancers in recurrent or metastatic stages.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were studies selected for inclusion?",{"text":118,"@type":114},"A PubMed and Google Scholar search identified studies of initially advanced or relapsed cases treated systemically, and selected studies were screened using PRISMA criteria, yielding 44 included studies out of 723 screened.",{"name":120,"@type":111,"acceptedAnswer":121},"How did treatment response relate to overall survival?",{"text":122,"@type":114},"Responders had better overall survival than non-responders, with a median time of 38 versus 18.7 months (P \u003C 0.001).",{"name":124,"@type":111,"acceptedAnswer":125},"Which treatments showed subtype-specific effectiveness?",{"text":126,"@type":114},"Anti-HER2 therapy was more effective for salivary duct carcinoma, while chemotherapy was more effective for adenoid cyst carcinoma.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},332629,1790432212,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":46},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","ORIGINAL RESEARCH  \nSystemic treatments in recurrent or metastatic salivary gland cancer: a systematic review  \nD. Prost1, 2􀀁, S. Iseas1, M. Gatineau1, J. Adam3, S. Cavalieri4, 5, C. Bergamini4, L. Licitra4, 5 & É . Raymond1  \n1Oncology Department, Hôpitaux Paris, Saint-Joseph Marie-Lannelongue, Paris; 2Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle Epinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2 Institute de Neurologie, Paris; 3Pathology Department, Hôpitaux Paris Saint-Joseph Marie-Lannelongue, Paris, France; 4Head and Neck Medical Oncology Department, Fondazione IRCCS, Istituto Nazionale dei Tumori di Milano, Milan; 5Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy  \nAvailable online xxx  \nBackground: Salivary gland cancers are infrequent and pose a challenge owing to their histological diversity and varied clinical behavior, making the selection of optimal systemic treatments for advanced or recurrent stages difficult. This systematic review aims to assess overall survival outcomes and systemic treatment responses across four types of salivary cancers.  \nMethods: A PubMed and Google Scholar search identified studies involving initially advanced or relapsed cases undergoing systemic treatment. Studies with clear, individualized data on treatment responses and outcomes were selected based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. Of the 723 studies screened, 44 met our inclusion criteria.  \nResults: A total of 426 cases of recurrent/metastatic salivary gland cancer, mostly salivary duct carcinoma (SDC; n ¼ 219) and adenoid cyst carcinoma (ACC; n ¼ 167), were included. Histomolecular markers were heavily associated with histology, with HER2 overexpression and androgen receptor nuclear expression typically found in SDC andadenocarcinoma not otherwise specified cases and KIT overexpression only in ACC. The response rates were associated with specific receptor blockage, with trastuzumab plus chemotherapy, and bicalutamide being the most effective (overall response rate 80% and 42 .8%, respectively) . Moreover, the response to treatment positively influenced overall survival (responders 38 versus non-responders 18 .7 median months; P \u003C 0.001) . In this retrospective analysis of a particular cohort, survival outcomes per histology types showed that anti-human epidermal growth factor receptor 2 therapy was more effective for SDC, while chemotherapy was more effective for ACC.  \nConclusion: Systemic treatments contribute to the survival of patients with salivary gland cancer at relapsed or newly advanced stages. The response to treatment is heavily influenced by histological subtype and treatment specificity. Key words: salivary gland cancer, systematic review, anti-HER2, androgen deprivation therapy  \nINTRODUCTION  \nSalivary gland carcinomas represent w20% of all salivary gland tumors and are characterized by substantial clinical, histological, and molecular heterogeneity.1,2 These malignancies can arise from any major or minor salivary glands and predominantly affect middle-aged men, exhibiting diverse histological subtypes and histotype-specific molecular markers, including androgen receptor (AR), HER2, PI3KCA.3-11  \n*Correspondence to: Dr Diego Prost, 185, rue Raymond Losserand e 75014 Paris, France. Tel: þ330144128000  \nE-mail: [diprost@ghpsj.fr](diprost@ghpsj.fr) (D. Prost).  \n2059-7029/© 2024 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)).  \nThe clinical presentation of salivary gland carcinomas poses a challenge, with some tumors demonstrating rapid progression through multiple lines of treatment, whereas others remain stable despite the presence of meta","cbCaihAmb760qlul","https://ap.wps.com/l/cbCaihAmb760qlul","pdf",1098556,"English","# Background\n# Methods\n# Results\n## Histology and biomarkers\n## Treatment response and survival\n# Conclusion","[{\"question\":\"What was the main goal of this systematic review?\",\"answer\":\"To assess overall survival outcomes and systemic treatment responses across four types of salivary gland cancers in recurrent or metastatic stages.\"},{\"question\":\"How were studies selected for inclusion?\",\"answer\":\"A PubMed and Google Scholar search identified studies of initially advanced or relapsed cases treated systemically, and selected studies were screened using PRISMA criteria, yielding 44 included studies out of 723 screened.\"},{\"question\":\"How did treatment response relate to overall survival?\",\"answer\":\"Responders had better overall survival than non-responders, with a median time of 38 versus 18.7 months (P \\u003c 0.001).\"},{\"question\":\"Which treatments showed subtype-specific effectiveness?\",\"answer\":\"Anti-HER2 therapy was more effective for salivary duct carcinoma, while chemotherapy was more effective for adenoid cyst carcinoma.\"}]","Systemic treatments in recurrent or metastatic salivary gland cancer - a systematic review | PDF",1789998959]